TBPH

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.

Wall Street analysts forecast TBPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TBPH is 28.60 USD with a low forecast of 13.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Theravance Biopharma Inc revenue for the last quarter amounts to 19.99M USD, increased 18.51 % YoY.

Theravance Biopharma Inc. EPS for the last quarter amounts to 0.07 USD, decreased -126.92 % YoY.

Theravance Biopharma Inc (TBPH) has 97 emplpoyees as of January 10 2026.

Today TBPH has the market capitalization of 964.80M USD.